SCHEMBL26969367

SCHEMBL26969367

Cc1ccc(S(=O)(=O)n2c(F)c(Br)c3cc(F)cnc32)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.43
PTGDR2 Q9Y5Y4 4/20 0.41
HTR6 P50406 1/20 0.38
PKM P14618 1/20 0.36
TSHR P16473 1/20 0.36
CYP2C19 P33261 1/20 0.36
ALDH3A1 P30838 3/20 0.36
NOD1 Q9Y239 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
POLB P06746 1/20 0.36
HTT P42858 1/20 0.36
ENPP3 O14638 1/20 0.35
ENPP1 P22413 1/20 0.35
CCKAR P32238 1/20 0.35
GAA P10253 2/20 0.35
MAPT P10636 1/20 0.35
CXCL8 P10145 1/20 0.34
NOD2 Q9HC29 1/20 0.34
ABL1 P00519 1/20 0.34
BCR P11274 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20575787 0.85 LMNA (0.42) LMNAPTGDR2HTR6ALDH3A1
SCHEMBL30321179 0.85 LMNA (0.42) LMNAPTGDR2HTR6ALDH3A1
SCHEMBL30321290 0.84 AGTR1 (0.44) LMNAPTGDR2CYP2C19ALDH3A1NOD1
SCHEMBL29605389 0.82 PTGDR2 (0.41) LMNAPTGDR2HTR6PKMTSHR
SCHEMBL31150779 0.80 ENPP3 (0.42) LMNAPTGDR2PKMALDH3A1NOD1
SCHEMBL29604690 0.78 PTGDR2 (0.46) LMNAPTGDR2PKMTSHRALDH3A1
SCHEMBL14685251 0.78 CA1 (0.46) LMNAPTGDR2HTR6PKMTSHR
SCHEMBL29604791 0.78 CA1 (0.46) LMNAPTGDR2HTR6PKMTSHR
SCHEMBL20502474 0.76 PTGDR2 (0.41) LMNAPTGDR2PKMTSHRCYP2C19
SCHEMBL473682 0.76 LMNA (0.43) LMNAPTGDR2HTR6PKMCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230416256-A1 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE JANSSEN PHARAMCEUTICA NV (BE) 2023-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416256-A1 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE NFKBIA, IKBKB, NFRKB LMNA 2917/4885PTGDR2 3131/4885HTR6 4574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.